Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 4/20 | 0.79 |
| ▸ | MAPT | P10636 | 2/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.55 |
| ▸ | BLM | P54132 | 1/20 | 0.55 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | NADK | O95544 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.45 |
| ▸ | HSPA8 | P11142 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL56019 | 1.00 | PNP (0.79) | PNPMAPTCYP3A4MEN1KMT2A | |
| SCHEMBL12150662 | 1.00 | PNP (0.79) | PNPMAPTCYP3A4MEN1KMT2A | |
| SCHEMBL56018 | 1.00 | PNP (0.79) | PNPMAPTCYP3A4MEN1KMT2A | |
| SCHEMBL14941501 | 1.00 | PNP (0.79) | PNPMAPTCYP3A4MEN1KMT2A | |
| SCHEMBL10117789 | 1.00 | PNP (0.79) | PNPMAPTCYP3A4MEN1KMT2A | |
| SCHEMBL23202308 | 1.00 | PNP (0.79) | PNPMAPTCYP3A4MEN1KMT2A | |
| SCHEMBL12746818 | 1.00 | PNP (0.79) | PNPMAPTCYP3A4MEN1KMT2A | |
| SCHEMBL2774442 | 1.00 | PNP (0.79) | PNPMAPTCYP3A4MEN1KMT2A | |
| Water SCHEMBL5501671 | 0.99 | PNP (0.78) | PNPMAPTCYP3A4MEN1KMT2A | |
| Water SCHEMBL5501677 | 0.99 | PNP (0.78) | PNPMAPTCYP3A4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10344261-B2 | Immunomodulatory conjugates | ASCEND BIOPHARMACEUTICALS LTD (AU) | 2019-07-09 | — | — | US | disclosed |
| US-20150030626-A1 | IMMUNOMODULATORY CONJUGATES | Ascend Biopharamaceuticals Ltd (AU) | 2015-01-29 | — | — | US | disclosed |
| EP-2399588-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | Merck Sharp & Dohme Corp. (US) | 2011-12-28 | — | — | EP | disclosed |
| EP-2360166-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | Merck Sharp & Dohme Corp. (US) | 2011-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10344261-B2 | Immunomodulatory conjugates | CLEC4M, TLR3, CD74 | PNP 3240/4885MAPT 2147/4885CYP3A4 4440/4885 |
| US-20150030626-A1 | IMMUNOMODULATORY CONJUGATES | CLEC4M, TLR3, CD74 | PNP 3240/4885MAPT 2147/4885CYP3A4 4440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.